These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 11418459

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
    Robak T.
    Leuk Lymphoma; 2004 Feb; 45(2):205-19. PubMed ID: 15101704
    [Abstract] [Full Text] [Related]

  • 9. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond.
    Dumont FJ.
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):23-35. PubMed ID: 12113063
    [Abstract] [Full Text] [Related]

  • 10. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.
    Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H.
    J Clin Oncol; 1997 Apr; 15(4):1567-74. PubMed ID: 9193354
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine.
    Montillo M, Cafro AM, Tedeschi A, Brando B, Oreste P, Veronese S, Rossi V, Cairoli R, Pungolino E, Morra E.
    Haematologica; 2002 Jul; 87(7):695-700; discussion 700. PubMed ID: 12091119
    [Abstract] [Full Text] [Related]

  • 12. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    Hale G, Slavin S, Goldman JM, Mackinnon S, Giralt S, Waldmann H.
    Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia.
    Kennedy B, Rawstron A, Carter C, Ryan M, Speed K, Lucas G, Hillmen P.
    Blood; 2002 Mar 15; 99(6):2245-7. PubMed ID: 11877305
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Minimal residual disease assessment in chronic lymphocytic leukaemia.
    Sayala HA, Rawstron AC, Hillmen P.
    Best Pract Res Clin Haematol; 2007 Sep 15; 20(3):499-512. PubMed ID: 17707836
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia--change of regimen needed?
    Rieger K, Von Grünhagen U, Fietz T, Thiel E, Knauf W.
    Leuk Lymphoma; 2004 Feb 15; 45(2):345-9. PubMed ID: 15101722
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.